Annexon Biosciences has announced significant progress across its pipeline of classical complement-mediated neuroinflammatory disease therapies, including positive regulatory momentum...
INVO Fertility Returns to Core Business, But Challenges Remain INVO Fertility reported second-quarter 2025 financial results, marking a return...
Cosciens Biopharma is streamlining its operations and sharpening its focus by voluntarily delisting from the Nasdaq stock market, while...
Inhibikase Therapeutics is advancing IKT-001, a prodrug of imatinib mesylate, towards a Phase 2b clinical trial for pulmonary arterial...
Eledon Pharmaceuticals’ recent Q2 2025 update highlights the emerging potential of its anti-CD40L antibody, tegoprubart, in the complex landscape...
Fortress Biotech’s recent Q2 2025 financial results reveal a company at a pivotal juncture, transitioning from a predominantly development-focused...
IO Biotech’s Phase 3 trial for Cylembio, a potential first-in-class off-the-shelf therapeutic cancer vaccine, in combination with Keytruda (pembrolizumab),...
Bolt Biotherapeutics’ recent financial report reveals a company navigating the challenging biotech landscape, prioritizing its next-generation claudin 18.2 ISAC,...
Pyxis Oncology, a clinical-stage ADC developer, reported second-quarter financials and pipeline updates, highlighting progress in its lead program, micvotabart...
Annexon Biosciences is accelerating its push into the complement-mediated disease market, reporting positive clinical progress across its pipeline and...
